Receptor, TNFR2, Identified as Target for Immunotherapy – Immuno-Oncology News
Immuno-Oncology News |
Receptor, TNFR2, Identified as Target for Immunotherapy
Immuno-Oncology News Antibody immunotherapy is showing great promise for combatting cancer. Several immune checkpoint inhibitors — including Keytruda (pembrolizumab), Opdivo (nivolumab), and Yervoy (ipilimumab) — dampen the tumor’s immunosuppressive signals and … |
Xconomy |
StemBioSys Taps VWR to Distribute Stem Cell Products in US, Canada
Xconomy San Antonio — StemBioSys has signed a deal to have its stem cell production products distributed in the U.S. and Canada by VWR (NASDAQ: VWR), a distributor of lab products to the life sciences industry, according to CEO Bob Hutchens. StemBioSys had a … |
Phys.Org |
CRISPR meets single-cell sequencing in new screening method
Phys.Org Genome editing using CRISPR/Cas9 “gene scissors” is a powerful tool for biological discovery and for identifying novel drug targets. In pooled CRISPR screens, a large number of cells are edited simultaneously using CRISPR guide-RNAs against thousands … |
EurekAlert (press release) |
CRISPR meets single-cell sequencing in new screening method
EurekAlert (press release) (Vienna, 19 January 2017) Genome editing using CRISPR/Cas9 “gene scissors” is a powerful tool for biological discovery and for identifying novel drug targets. In pooled CRISPR screens, a large number of cells are edited simultaneously using CRISPR … |
FierceBiotech |
Ex-GSK rare disease head moves to Genenta
FierceBiotech He joins Milan, Italy-based Genenta Science, a biotech focused on hematopoietic stem cell gene therapy in cancer, as its new CMO. Russo has worked on gene therapy before as he was head of R&D at London-based GSK’s rare disease unit, helping get its … |
FierceBiotech |
Ex-GSK rare disease head moves to Genenta
FierceBiotech He joins Milan, Italy-based Genenta Science, a biotech focused on hematopoietic stem cell gene therapy in cancer, as its new CMO. Russo has worked on gene therapy before as he was head of R&D at London-based GSK’s rare disease unit, helping get its … |